Acuta Capital Partners’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Acuta Capital Partners’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,000	Closed	-$4.2M	–	54
2021 Q3	$4.2M	Sell	13,000 -10,920	-46%	-$3.19M	1.48%	19
2021 Q2	$6.21M	Buy	23,920 +4,220	+21%	+$1.29M	2.48%	15
2021 Q1	$7.6M	Buy	+19,700	New	+$7.95M	2.74%	13

Other funds holding VINC

SRC

Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Acuta Capital Partners's VINC Position: Q4 2021 in Review

Acuta Capital Partners sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2021, closing a stake of 13,000 shares — an estimated $4.2M sold.

Acuta Capital Partners first reported a position in VINC in Q1 2021 and held it in 3 quarters. The position peaked at $7.6M in Q1 2021. 55 funds tracked by Wall St. Rank hold VINC as of Q4 2021.

Acuta Capital Partners reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Acuta Capital Partners sold 13,000 Vincerx Pharma, Inc. Common Stock shares in Q4 2021, an estimated $4.2M.
Acuta Capital Partners first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
Acuta Capital Partners's Vincerx Pharma, Inc. Common Stock position peaked at $7.6M in Q1 2021.
55 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2021.

Based on Acuta Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.